Animal Health company, MSD, which owns brands including Bravecto Chew and Bravecto Plus, has re-appointed Zenith Sydney to its media planning and buying account in Australia, following a competitive pitch.
MSD offer one of the industry’s most innovative portfolios, spanning products for the prevention, treatment and control of disease in farm and companion animal species. With a strong focus on solutions-driven products and services, MSD is dedicated to continually earning the trust of its customers.
In extending its eight year partnership with MSD, Zenith will keep the Bravecto brand competitive in market, with the objective to switch competitive users to Bravecto Chew and Bravecto Plus for dogs and cats respectively. The brand will focus on encouraging pet owners to be proactive about treating their pets compliantly, providing them with peace of mind for their pets’ long-lasting protection.
Says Vanessa Gattellari, ANZ marketing lead, MSD Animal Health: “MSD Animal Health is pleased to be continuing our long standing working relationship with Zenith as our media planning and buying account for Bravecto in Australia. The Zenith team’s passion and dedication to Bravecto has been evident throughout the eight years they have been working on the brand, and was present throughout the pitch process. MSD Animal Health are pleased to continue working with Zenith and excited for the future of Bravecto.”
Says Jonny Cordony, managing director, Zenith Sydney: “The competitive pitch process gave us opportunity to portray our passion, dynamic approach within the category, and overall new thinking for the Bravecto brand. I am proud to say that it is the team’s deep knowledge of the category that helped to strengthen our long standing partnership – and we are excited to continue to accelerate change for MSD into 2023 and beyond.”